glp-1 gip and glucagon receptor agonists are increasingly used to treat type 2 diabetes obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal Dual GIP/GLP-1 receptor agonists: New

Yes, L carnitine has been shown to improve sperm motility by boosting energy levels in sperm cells

In addition to activating GLP-1 receptors, it also targets GIP receptors, which are involved in metabolic regulation and insulin response

These findings are consistent with previous real-world studies conducted among people with T2DM or obesity [13, 14]

This review highlights the potential clinical benefits of GLP-1 receptor agonists and co-agonists as tools in the management of obesity

SAME DAY Foot and Ankle URGENT CARE Need immediate foot or ankle care

In particular, diabetes-related hyperglycemia acts through oxidative stress, fibrosis and severe inflammation in the reproductive tract, as demonstrated by the increase in serum transforming growth factor beta (TGF-), malonylaldehyde (MDA), and pentraxin-3 (PTX-3), with reduction in ovarian reserve and antimullerian hormone (AMH)